Trials / Not Yet Recruiting
Not Yet RecruitingNCT07374419
Atamparib in Patients With Advanced Solid Tumors
A Phase Ib/II Study of Atamparib in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | atamparib escalation levels | Bid, Oral, escalating at different dose levels |
| DRUG | atamparib RP2D | Bid, oral, RP2D |
Timeline
- Start date
- 2026-02-10
- Primary completion
- 2028-07-31
- Completion
- 2029-01-31
- First posted
- 2026-01-28
- Last updated
- 2026-01-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07374419. Inclusion in this directory is not an endorsement.